Vinay Gulati, MD
Nuclear Cardiology · Hartford, CTNPI 1275832370
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.4% of the total across 403 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 18.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $2,169 and has fallen 64.5% since, to $771 in 2025.
Across 403 payments — averaging $20.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Actelion Pharmaceuticals US, Inc.$2K
- Amgen$982
- Novartis$674
- Pfizer$654
- Bayer$551
- AstraZeneca$508
- plus $3K from 21 others
What the payments were for
- Food & beverage$7,92795%
- Education$2964%
- Other$901%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Actelion Pharmaceuticals US, Inc. | 46 | $1,554 |
| Amgen | 52 | $982 |
| Novartis | 39 | $674 |
| Pfizer | 41 | $654 |
| Bayer | 26 | $551 |
| AstraZeneca | 27 | $508 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 26 | $484 |
| Johnson & Johnson | 28 | $478 |
| Esperion Therapeutics, Inc. | 21 | $393 |
| E.r. Squibb & Sons, L.L.C. | 22 | $382 |
| Boehringer Ingelheim | 17 | $321 |
| Novo Nordisk | 10 | $300 |
| Merck | 13 | $239 |
| Abbott | 9 | $196 |
| Medtronic | 5 | $123 |
| Baxter Healthcare | 2 | $114 |
| Regeneron Healthcare Solutions, Inc. | 4 | $68 |
| Kowa Pharmaceuticals America, Inc. | 2 | $53 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $37 |
| Amryt Pharma Holdings Ltd | 2 | $37 |
| G Medical Diagnostic Services, Inc. | 2 | $32 |
| Amarin Pharma, Inc. | 2 | $30 |
| Boston Scientific | 1 | $28 |
| Lexicon Pharmaceuticals, Inc. | 1 | $23 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $18 |
| Medicomp Inc | 1 | $18 |
| Daiichi Sankyo Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Wegovy$120
How this compares
Too few nuclear cardiology providers in Connecticutto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 121 | $155,905 |
| EntrestoSacubitril/Valsartan | 63 | $84,331 |
| XareltoRivaroxaban | 21 | $32,395 |
| JardianceEmpagliflozin | 16 | $16,604 |
| FarxigaDapagliflozin Propanediol | 13 | $13,651 |
| BrilintaTicagrelor | 16 | $6,880 |
| Metoprolol Succinate | 261 | $3,904 |
| Clonidine | 22 | $3,164 |
| Atorvastatin Calcium | 182 | $2,535 |
| Flecainide Acetate | 54 | $2,354 |
| Amlodipine Besylate | 259 | $2,188 |
| Losartan Potassium | 204 | $2,141 |
| Rosuvastatin Calcium | 70 | $1,601 |
| Ezetimibe | 23 | $1,549 |
| Carvedilol | 118 | $1,147 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $654 | $155,905121 claims |
| NovartisEntresto | $674 | $84,33163 claims |
| Johnson & JohnsonXarelto | $478 | $32,39521 claims |
| AstraZenecaFarxiga, Brilinta | $508 | $20,53129 claims |
| Boehringer IngelheimJardiance | $321 | $16,60416 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few nuclear cardiology providers in Connecticuton file to place this against a meaningful peer group, so we don't.
Other nuclear cardiology in Hartford
- Sanjeev BhavnaniHartford$29K
- Gary HellerHartford$11K
- William DuvallHartford$10K
- Edward MillerNew Haven$36K
- Rahul GuptaNew Haven$24K
- Adam SchussheimFairfield$10K
- Mehran SadeghiWest Haven$101
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.